Kamada Ltd. Reports Strong Q3 2025 Financial Results with 30% Profit Growth
Kamada Ltd. reported strong Q3 2025 financial results, achieving a 13% year-over-year revenue growth to $47 million and a 34% increase in adjusted EBITDA. For the first nine months, revenues rose by 11% to $135.8 million. The company maintains a positive outlook, reiterating full-year revenue guidance of $178 million to $182 million. Kamada is advancing clinical trials and expanding plasma collection operations, including FDA approval for its Houston facility. Analysts rate (IL:KMDA) stock as a Buy with a price target of ILs2519.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An announcement from Kamada ( (IL:KMDA) ) is now available.
Kamada Ltd. reported strong financial results for the third quarter and first nine months of 2025, with a significant increase in profitability. The company achieved a 13% year-over-year revenue growth in the third quarter, reaching $47 million, and a 34% increase in adjusted EBITDA. For the first nine months, revenues rose by 11% to $135.8 million, with a 35% increase in adjusted EBITDA. Kamada’s financial performance is supported by its diverse product portfolio and strategic business development initiatives. The company maintains a positive outlook for the remainder of 2025, reiterating its full-year revenue guidance of $178 million to $182 million and adjusted EBITDA of $40 million to $44 million. Kamada is also advancing its clinical trials and expanding its plasma collection operations, including receiving FDA approval for its Houston facility.
The most recent analyst rating on (IL:KMDA) stock is a Buy with a ILs2519.00 price target. To see the full list of analyst forecasts on Kamada stock, see the IL:KMDA Stock Forecast page.
More about Kamada
Kamada Ltd. is a global biopharmaceutical company specializing in the development and commercialization of specialty plasma-derived products. The company focuses on providing treatments for rare and serious conditions, with a diverse portfolio that includes products like GLASSIA® and VARIZIG®.
YTD Price Performance: -0.58%
Average Trading Volume: 53,757
Technical Sentiment Signal: Hold
Current Market Cap: ILs1.25B
For an in-depth examination of KMDA stock, go to TipRanks’ Overview page.
